Our round-up of the major patent issues affecting pharma and biotech that emerged on the legal, market and policy fronts last month
In an exclusive interview, MPEG LA’s Kristin Neuman says that a pool is on its way despite the UCal v Broad stand-off and talks about the future of licensing in biotech’s ‘golden age’
Lewis Silkin’s acquisition of Ablett & Stebbing is a first and demonstrates just how far things have moved in a once conservative market
The Chinese company also revealed its royalty outflow – $6 billion since it took its first licence in 2001, 80% of which has gone to US companies
The latest judgment is one of only a few to provide an indication of when the courts will grant the pre-emptive litigation defence remedy, which was issued for the first time in 2017
Special IAM boardroom session at IPBC Global 2019 focuses on how to get more women involved in senior positions in the global IP market - and why everyone will win when it happens
Ongoing royalty negotiations are revealed after US network operator reportedly notifies government. Why the conflict, which follows a 2016 dispute with T-Mobile, may alarm Nokia and Ericsson
Move designed to influence debate in Europe and comes on same day as implementers publish their own guidelines.
Transfer of microfluidics tech comes as San Diego-based Illumina faces a fierce IP fight with an upstart Chinese rival
Following successful invalidation petitions lodged by Vivo against the German company, industry sources tell IAM that Oppo, Xiaomi and Meizu also face SEP assertions in specialised IP courts
Recent decisions in Germany, the UK, the Netherlands and France have shed much greater light on where the continent’s top patent litigation venues are heading on FRAND-related disputes
Opinion from East Texas judge adds to earlier win for Swedish telco in lawsuit against HTC, but looming appeals give rights owners plenty to think about
With the giant brewer facing off against Heineken in court, Michael Swita sets out how innovation and patents are becoming a far bigger consideration in the industry
Shenzhen BGI was once the biggest purchaser of Illumina’s gene sequencing machines. Now the two are on opposite sides of an expanding patent battle
Having been the subject of a key decision from the UK Supreme Court, plausibility has been an increasingly important topic for life sciences rights holders to consider in both patent prosecution and litigation.